NasdaqCM - Delayed Quote • USD
Daxor Corporation (DXR)
At close: April 26 at 4:00 PM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Michael Richard Feldschuh | Chairman, President & CEO | 100k | -- | 1969 |
| Mr. Jonathan Adam Feldschuh | Chief Scientific Officer & Director | 127.92k | -- | 1965 |
| Mr. Robert J. Michel CPA, CPA, M.B.A. | CFO, Chief Compliance Officer & Corporate Secretary | -- | -- | 1957 |
| Ms. Linda Cooper | Vice President of Development & Operations | -- | -- | -- |
| Ms. Kathryn A. Kornafel | Senior VP of Marketing & Commercial Development | -- | -- | -- |
| Mr. Guido Manzo | Vice President of Sales | -- | -- | -- |
| Ms. Jean Oertel | Senior Vice President Commercialization & Customer Experience | -- | -- | -- |
Daxor Corporation
109 Meco Lane
Oak Ridge, TN 37830
United States
- Sector:
- Healthcare
- Industry: Medical Instruments & Supplies
Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Corporate Governance
Daxor Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Mar 25, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 19, 2024N-CSR/A: Periodic ReportsSee Full Filing
- Mar 15, 2024N-CSR: Periodic ReportsSee Full Filing
- Feb 29, 2024NT-NCSR: Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report)See Full Filing
- Jan 02, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Mar 25, 2024
Daxor Corporation Earnings Call
Related Tickers
HRAL Hear AtLast Holdings, Inc.
0.0010
0.00%
PRM.MC Prim, S.A.
10.25
+2.50%
BIOT.ST Biotage AB (publ)
165.50
+1.47%
GMVDF G Medical Innovations Holdings Ltd
0.0200
+17.65%
ALIF-B.ST AddLife AB (publ)
98.65
+2.02%
TECN.SW Tecan Group AG
332.60
+1.65%
MLSS Milestone Scientific Inc.
0.5600
-1.75%
BONEX.ST Bonesupport Holding AB (publ)
232.00
-2.36%
NYXH Nyxoah S.A.
10.62
-1.30%
ALC.SW Alcon Inc.
72.00
+0.61%